Biotech & AI drug discoverySTAT — Biotech

STAT+: PepGen says early trial for muscular dystrophy drug looks promising

PepGen says an early trial of its muscular dystrophy drug candidate looks promising, with the company reporting it corrects more of the genetic stutter found in myotonic dystrophy type 1. The claim comes from the company and reflects an early-stage trial.

AI summary · generated only from source feed metadata; consult original

Source published2026-11-10T12:05:00+00:00

Published here2026-11-10T12:22:46+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/11/10/muscular-dystrophy-dm1-pepgen-pgn-edodm1-early-results/

Original headline

STAT+: PepGen says early trial for muscular dystrophy drug looks promising

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.